Extensive Informed Consent May Not Improve Patients’ Understanding of Their Cancer Care

Providing detailed informed consent does not appear to improve patients’ comprehension, according to a study published on researchsquare.com as a preprint and not yet peer reviewed.

Key Takeaway

  • Patients with cancer are equally likely to understand their treatment when provided long, involved informed consent forms designed for clinical trials and shorter, less comprehensive forms used in routine care.

Why This Matters

  • The findings suggest that the significant efforts involved in providing informed consent to patients in clinical trials may have limited value and that these procedures can be improved.

Study Design

  • The investigators compared comprehension and satisfaction between 82 newly diagnosed cancer patients who consented to clinical trials and 89 who consented to standard chemotherapy.

  • Both groups filled out a questionnaire. Trial participants also had a structured interview, and routine care patients completed a follow-up questionnaire 6 months later.

Key Results

  • Trial consent forms ran up to 40 pages; the routine care form was six pages.

  • Patients in both groups said they understood and were satisfied with the information provided.

  • However, 20% of patients in both groups could not name their cancer diagnosis correctly.

  • In addition, about 20% of patients in both groups had trouble understanding the forms, and 10% in both did not read the information.

  • Of patients in the clinical trial group, 89% said they understood the purpose of the trial, 9% reported only a partial understanding, and 2% did not understand the purpose at all.

  • In addition, 40% said they read their consent documents in less than 15 minutes.

  • For those receiving routine care, 75% said they knew the goal of treatment, 18% said the goal was unclear, and 7% did not know the treatment goal at all.

Limitations

  • The questionnaire has not been validated outside of the study institution.

  • Patients who were interviewed might have felt pressured to give positive answers.

  • The goal of therapy was cure in the trial group, but it was often palliative in the routine care group, which might have led to selection bias.

Disclosures

  • The authors reported no study funding.

  • The two senior authors are advisors, speakers, and/or researchers for several companies, including Janssen and Novartis.

This is a summary of a preprint research study, “Struggling with Extensive Informed Consent Procedures for Cancer Trails – Is There Even a Benefit for the Patients?” The study has not been peer reviewed. The full text can be found at researchsquare.com.

M. Alexander Otto is a physician assistant with a master’s degree in medical science. He is an award-winning medical journalist who worked for several major news outlets before joining Medscape and is an MIT Knight Science Journalism fellow. Email: aotto@mdedge.com.

For more news, follow Medscape on Facebook, Twitter, Instagram, and YouTube.

Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
7 Foods That Are Good for Your Liver thumbnail

7 Foods That Are Good for Your Liver

1 Coffeed3sign//Getty ImagesOkay, we know it’s technically a beverage, but we’re putting this one first."The only food where there is clear evidence for a beneficial impact on your liver is coffee,” says Bansal. “Coffee consumption is associated with improvement in liver enzymes, especially in individuals with risk for liver disease."Those with pre-existing liver disease have
Read More
Remdesivir Sharply Cuts COVID Hospitalization Risk, Gilead Says thumbnail

Remdesivir Sharply Cuts COVID Hospitalization Risk, Gilead Says

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Remdesivir (Veklury, Gilead) was found to reduce some COVID-19 patients' risk of hospitalization by 87% in a phase 3 trial, the drug's manufacturer announced Wednesday in a press release. The randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of a 3-day…
Read More
Status de neurodesenvolvimento aos seis meses de idade em crianças com e sem exposição ao SARS-CoV-2 thumbnail

Status de neurodesenvolvimento aos seis meses de idade em crianças com e sem exposição ao SARS-CoV-2

Avalie o nosso conteúdo: Houve um erro fazendo sua requisição, por favor tente novamente! Obrigado!Sua avaliação é fundamental para que a gente continue melhorando o Portal Pebmed O Portal PEBMED é destinado para médicos e demais profissionais de saúde. Nossos conteúdos informam panoramas recentes da medicina. Caso tenha interesse em divulgar seu currículo na internet,…
Read More
Index Of News
Consider making some contribution to keep us going. We are donation based team who works to bring the best content to the readers. Every donation matters.
Donate Now

Subscription Form

Liking our Index Of News so far? Would you like to subscribe to receive news updates daily?

Total
0
Share